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FcγRI (CD64): an identity card for intestinal macrophages
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Abstract
Macrophages (MF) are becoming increasingly recognized as key cellular players in intestinal
immune homeostasis. However, differentiating MF from dendritic cells (DC) is often difficult, and
finding a specific phenotypic signature for intestinal MF identification has remained elusive. In
this issue of European Journal of Immunology Tamoutounour et al. identify CD64 as a specific
MF marker capable of discriminating DC from MF in the murine small and large bowel, and under
steady state and inflammatory conditions. The authors also propose a sequential ‘monocyte (Mo)-
waterfall’ model for intestinal MF differentiation, with implications for immune tolerance and
inflammation at the gut mucosal interface.
Mononuclear phagocytes, including MF and DC, are key components of innate and adaptive
immune responses. While DC subsets have been thoroughly characterized in different
tissues and under a variety of conditions, MF subsets and functions are much less
understood. This is in great part due to the lack of markers to reliably identify and isolate
MF in different tissues, including the gut. There is also a lack of consensus on how to
functionally define DC and MF. DC were initially defined as antigen presenting cells with
the capacity to activate naïve T cells. However, this definition is not accurate, as there are
situations in which efficient T cell priming can occur in the absence of DC [1, 2]. Moreover,
immature DC do not efficiently activate naïve T cells and therefore they could not be
included in this functional definition. Thus, DC subsets are currently identified using a
combination of phenotypic, functional, and ontogenetic criteria [3].
What is a macrophage?
MF are classically considered terminally differentiated non-migratory phagocytic cells,
which are not involved in priming naïve T cells. However, recent data indicate that, beyond
their phagocytic capacity, MF play an active and critical role in maintaining immune
tolerance. In fact, under normal conditions intestinal MF are non-inflammatory scavengers
of bacteria, and they are involved in expanding TREG in the lamina propria (LP) [3, 4]. On
the other hand, in some settings, such as during IBD, MF can become pro-inflammatory
cells [3, 4].
In the gut MF have been usually identified by their expression of MHC-II, CD11b,
fractalkine receptor (CX3CR1), F4/80, and by their lack of DC markers CD11c and CD103
[4]. However, CD11c can also be expressed at low/intermediate levels in intestinal LP MF,
and some investigators have denominated MHC-II+CD11b+CD11cint cells as MF [5, 6],
while others dubbed them as DC [7]. On the other hand, although CX3CR1 is preferentially
expressed in intestinal LP MF, some CD11b+ DC exhibit intermediate levels of this receptor
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[5]. Thus, there is an urgency to find specific phenotypic signatures capable of reliably
discriminating MF and DC in the gut mucosa under different conditions.
In this context, Tamoutounour et al. propose using the high-affinity IgG receptor gamma
chain FcγRI (CD64) to unambiguously label intestinal MF [8]. The authors show that CD64
can clearly discriminate MF from DC, even when MF express CD11cint (CD64+) or when
DC express CX3CR1int (CD64neg) (Table 1). Of note, while granulocytes also express
CD64, they can be excluded by their lack of MHC-II, high SSC, and their expression of
Ly6G. Importantly, the authors show that CD64 can be used as a reliable MF marker in both
small and large bowel, and under steady state or inflammatory conditions. Moreover, they
propose that CD64 could also be used to label intestinal MF in humans. However, as
discussed below, the expression of this marker in human MF might be less consistent than in
the murine system. Also, given the potential for CD64 modulation under some conditions
(discussed below), future work should assess whether the expression of this marker is
consistently stable and specific in MF under different inflammatory or infectious scenarios.
Mo-waterfall model for intestinal MF differentiation: steady state versus gut
inflammation
By combining CD64 with other classical markers described in Table 1, Tamoutounour et al.
propose a model in which blood Mo (Ly6ChighMHC-IInegCD64neg) enter to the intestinal LP
using CCR2. In the LP they lose Ly6C and reciprocally acquire MHC-II and CD64
expression [8]. Given the appearance of this labeling in the FACS plots, they described this
differentiation pattern as ‘Mo-waterfall’ (Fig. 1A). A similar differentiation pathway was
observed in a study that was published in parallel [9]. Of note, using elegant experiments
involving in vivo labeling as well as adoptive transfer of labeled monocytes, Tamoutounour
et al. convincingly demonstrated that the Mo-waterfall model of MF differentiation occurs in
the steady state and during gut inflammation.
Unexpectedly, the authors show that during intestinal inflammation there is a massive
recruitment of Mo to MLN, where they differentiate into MF [8]. Interestingly, in contrast to
DC migration from LP to MLN via lymphatics, Mo recruitment to MLN occurs directly
from the blood and not from the intestinal LP. In fact, while LP DC arrival to MLN is
abrogated in CCR7−/− mice, macrophage expansion in MLN during inflammation was not
affected in these mice [8]. Moreover, CCR7 was not required for triggering intestinal
inflammation, suggesting that MF (and not LP DC) are the key pathogenic cells, at least in
the tested IBD model. These observations challenge the conventional wisdom that intestinal
inflammation needs to be pathogenically associated with DC migration from LP to MLN. It
will be interesting to determine whether Mo entry to MLN also relies on CCR2. If so, it is
tempting to speculate that intestinal inflammation might induce CCR2-ligands in MLN (or
in IEC/LP, which then reach the MLN via lymphatics), hence recruiting CCR2+ blood
monocytes, which will give rise to MLN MF.
The Mo-waterfall model distinguishes four distinct stages in LP MF differentiation (P1 to
P4) [8, 9]. Interestingly, Tamoutounour et al. show that under inflammatory conditions MF
differentiation is blunted, reaching only the P2 stage in the LP and MLN
(F4/80negCX3CR1neg, Table 1, Fig. 1B). P2 MF express iNOS and produce pro-
inflammatory cytokines (IFNγ, TNFα) [8, 9]. How intestinal inflammation interferes and
skews MF differentiation in the gut remains to be determined. In this regard, lack of
CX3CR1 expression in P2 MF might preclude the generation of fully tolerogenic IL-10-
producing MF, promoting a pro-inflammatory phenotype. Supporting this view, mice
lacking CX3CR1 exhibit impaired oral tolerance and increased susceptibility to intestinal
inflammation [10, 11], an effect that was correlated with a lack of IL-10 expressing MF in
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CX3CR1−/− mice [10]. CX3CR1−/− mice also show a marked decrease in the numbers of
MF in the gut [11], suggesting that CX3CR1 might be involved in MF survival/turnover in
the LP. However, another report did not find a decrease in total MF in CX3CR1−/− mice,
although IL-10 production by MF was impaired in these mice [10].
Of note, although CX3CR1 is upregulated in vivo in the intestinal mucosa, this receptor is
not induced upon in vitro MF differentiation, suggesting that local microenvironmental
signals are needed to induce CX3CR1. However, although CX3CR1 is upregulated in gut
LP MF, it can also happen in extra-intestinal tissues, such as the lungs [12], implying that
the signals involved in modulating this receptor might not necessarily be gut-specific.
This newly proposed Mo-waterfall model for intestinal MF differentiation also implies that
CX3CR1neg (P1/P2) and CX3CR1+/high (P3/P4) MF, as well as pro-inflammatory (P2) or
tolerogenic (P4) MF, can all be positioned in a continuum spectrum of MF differentiation in
the LP, rather than each MF type being originated from independent precursors [8, 9]. Thus,
this new work not only describes a convenient and reliable marker for gut MF identification
and isolation in the mouse, but it also provides a novel conceptual framework that
potentially unifies previously published observations on intestinal DC and MF.
CD64 specificity, regulation, and therapeutic implications
CD64 expression and specificity
While Tamoutounour et al. clearly show that CD64 is a specific marker for intestinal MF in
the mouse, it should be noted that CD64 might not faithfully discriminate MF from DC in
extra-intestinal tissues. For example, a recent paper identified a migratory population of
Ly6ChighCD64+ DC in murine muscle (migratory monocyte-derived lymph node DC) [13].
While this Ly6ChighCD64+ DC population depended on CCR2 for their initial location in
muscle, in contrast to intestinal MF these cells can migrate to the draining lymph node in a
CCR7-dependent manner upon inflammation [13].
Moreover, in humans CD64 might not be expressed in all MF subsets in the intestinal LP. In
this regard, Tamoutounour et al. show that CD64 is expressed on CD14+ MF in humanized
mice and in biopsies from IBD patients. While the authors do not show whether
CD14negCD11cneg MF express CD64, other reports indicate that resting CD14neg MF do not
express CD64 and that this marker is preferentially expressed in inflammatory CD14+ MF in
human IBD [9, 14, 15]. Furthermore, one report did not show CD64 expression in human
intestinal MF, and only mild CD64 expression in vaginal MF [16]. While the reason for this
discrepancy is unclear, it might be related to differences in MF isolation techniques or to the
markers/gates used in each study. Finally, CD64 can be readily detected in human blood
monocytes [17, 18], suggesting that its expression in humans might be more ubiquitous,
especially outside the gut. In summary, in contrast to the murine model, CD64 might not be
a universal or specific marker for human intestinal MF.
CD64 induction and regulation
CD64 can be induced in MF by IFNγ [19], while IL-4 suppresses its expression in human
and murine MF [18, 20, 21]. Given that Th1 and Th2 cytokines reciprocally modulate CD64
(in vitro and in vivo), it will be interesting to assess whether MF differentially express CD64
in the context of Th1- or Th2-associated IBD models, or in mouse strains with a Th2 bias
(e.g., Balb/c). Of note, IL-10 also upregulates CD64 [22] and, at least in vitro, it can prevent
CD64 downmodulation by Th2 cytokines [23]. Given the relative abundance of IL-10 in the
intestinal compartment (even during inflammation [9]), this cytokine might sustain CD64
expression on MF, regardless of the Th1/Th2 environment.
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In vivo targeting of CD64 has been experimentally used to boost peripheral antigen-specific
antibody immune responses [24]. On the other hand, CD64 has been proposed as a
therapeutic target for eliminating activated MF in some inflammatory conditions, such as
arthritis [24, 25]. A downside is that CD64 can also be subverted by some pathogens for
invading MF and cause severe systemic infection [26].
Regarding immunomodulation, it has been described that immune complexes promote CD64
crosslinking in MF, increasing IL-10 and shutting down IL-12 production in vitro and in
vivo [27, 28]. While these effects of CD64 modulation might potentially be exploited to
increase tolerogenicity in the gut mucosa in the context of IBD, it has been shown that CD64
might also have a negative impact on some antibody-mediated therapies, at least in vitro
[29]. In particular, therapeutically used anti-TNFα antibodies (Infliximab and Adalimumab)
can stimulate CD64 via their Fc portion, inducing the production of pro-inflammatory
cytokines by human MF cell lines. Of note, this pro-inflammatory effect was not observed
with Certolizumab (anti-TNFα Fab’, lacking the Fc fragment) [29]. Thus, blocking CD64
might have a synergistic effect when using some of these anti-TNFα therapies in IBD.
However, given the seemingly antagonistic effects of CD64 modulation in different settings,
at this point it cannot be predicted the final outcome of harnessing CD64 in a therapeutic
context.
Concluding remarks
Tamoutounour et al. demonstrate that CD64 can be used as a reliable marker to define an
‘identity card’ for intestinal MF in the mouse. Future work needs to determine whether
CD64 is sufficiently stable and specific to label MF under different inflammatory settings.
The usefulness of CD64 in humans appears to be restricted to CD14+ inflammatory MF, but
this interpretation needs to be supported by additional work in human biopsies from patients
with and without active IBD.
In addition, the authors provide a sequential ‘Mo-waterfall’ model to define MF
differentiation stages in the intestinal LP. This conceptually new framework allows
positioning pro-inflammatory and tolerogenic MF in a continuum spectrum of gut MF
differentiation that can be disrupted during inflammation. Finally, while CD64 has been
targeted to boost or dampen peripheral immune responses in different experimental models,
additional data is needed to predict the outcome of modulating this pathway in the intestinal
mucosa.
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Figure 1. MF differentiation in the intestinal lamina propria
(A) ‘Mo-waterfall’ model (based on FACS plot pattern): Ly6Chi blood monocytes (Mo)
enter the intestinal lamina propria (LP) where they downregulate Ly6C and acquire the
expression of MHC-II and CD64, becoming macrophages (MF). (B) Left: under steady state
conditions, Mo enter to the LP in a CCR2-dependent manner. They first go through P1/P2
stages (CD64low/+F4/80negCX3CR1−/int) to finally become P3/P4 tolerogenic IL-10-
producing MF (CD64+F4/80+CX3CR1high). Right: during inflammation MF differentiation
is blunted, reaching only the P2-MF stage and becoming pro-inflammatory iNOS+TNFα+
MF. In this setting there is also massive P2-MF infiltration in mesenteric lymph nodes
(MLN), which might also depend on CCR2.
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